Drug intelligence / Profile preview

AMUFORT

Development stage: Unknown
Lead developer: Sanifortpharma
Modality: Small Molecules
Administration: Oral

Overview

AMUFORT is a dietary supplement developed by Sanifortpharma designed to support the immune system and respiratory health. It is primarily indicated for the management of colds and upper respiratory infections. The formulation features *Pelargonium sidoides* root extract as its primary active component, which is known for its properties in strengthening natural resistance and protecting the respiratory tract. The product is available in two versions: an adult formulation containing thyme, *Eucalyptus globulus*, and *Primula veris*, and a "Kids" formulation containing propolis, *Eucalyptus globulus*, and *Pinus sylvestris*. It is marketed as a natural alternative for increasing resistance against bacteria, viruses, and common winter ailments.

Brand names: AMUFORT

Beyond the preview

Go deeper on AMUFORT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMUFORT.

Explore the full profile